TY - JOUR
T1 - Pseudoprogression and MGMT status in glioblastoma patients
T2 - Implications in clinical practice
AU - Fabi, Alessandra
AU - Russillo, Michelangelo
AU - Metro, Giulio
AU - Vidiri, Antonello
AU - Di Giovanni, Salvatore
AU - Cognetti, Francesco
PY - 2009/7
Y1 - 2009/7
N2 - Pseudoprogression (PsPD) is a pathological feature recently reported by some authors in malignant glioma patients treated with radiotherapy in combination with temozolomide. In radiological imaging, it is shown as an increase in the size of the tumor lesion and contrast enhancement occurring within a few months from the completion of radio-chemotherapy without worsening of the neurological signs and symptoms. In 21%-50% of the patients, the same lesion disappears a few months after its appearance. In 12 glioblastoma patients treated with radio-chemotherapy, 4 cases of early radiological progression without discontinuation of temozolomide treatment are reported. At the sunsequent tumor assessment, 2 cases (13%) were revealed to be PsPD. The two patients who experienced PsPD had the longest progression and survival times of all patients. In both patients with PsPD, the 06-methylguanine-DNA methyltransferase (MGMT) promoter was found to be methylated. The PsPD phenomenon opens the prospect of a new era for the management of glioblastoma patients undergoing radio-chemotherapy.
AB - Pseudoprogression (PsPD) is a pathological feature recently reported by some authors in malignant glioma patients treated with radiotherapy in combination with temozolomide. In radiological imaging, it is shown as an increase in the size of the tumor lesion and contrast enhancement occurring within a few months from the completion of radio-chemotherapy without worsening of the neurological signs and symptoms. In 21%-50% of the patients, the same lesion disappears a few months after its appearance. In 12 glioblastoma patients treated with radio-chemotherapy, 4 cases of early radiological progression without discontinuation of temozolomide treatment are reported. At the sunsequent tumor assessment, 2 cases (13%) were revealed to be PsPD. The two patients who experienced PsPD had the longest progression and survival times of all patients. In both patients with PsPD, the 06-methylguanine-DNA methyltransferase (MGMT) promoter was found to be methylated. The PsPD phenomenon opens the prospect of a new era for the management of glioblastoma patients undergoing radio-chemotherapy.
KW - Concomitant radiochemotherapy
KW - Glioblastoma
KW - Pseudoprogression
KW - Radiological assessment
UR - http://www.scopus.com/inward/record.url?scp=69249184418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69249184418&partnerID=8YFLogxK
M3 - Article
C2 - 19596935
AN - SCOPUS:69249184418
VL - 29
SP - 2607
EP - 2610
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 7
ER -